Original Publication Date: 1 November, 2015
Publication / Source: Immunotherapy
Authors: Leisha A Emens, Vincent K Tuohy & Sasha E Stanton
Immunotherapy invited leading experts in the field to share their thoughts on two key immunotherapeutic strategies in the field of breast cancer research, vaccines and checkpoint inhibitors.
Interviewed by Ellen Clarke (Commissioning Editor, Future Science Group).
Historically breast cancer has been considered immunologically silent. Patients have had limited access to the types of immunotherapy available to melanoma and lung cancer patients, but this could all be set to change as recent preclinical and clinical studies have highlighted the potential of immunotherapy for breast cancer. Breast cancer is now one of the major cancer types for which new immune-based treatments are being developed.
Leisha A Emens: Department of Oncology, Johns Hopkins University School of Medicine, Kimmel Cancer Center at Johns Hopkins